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obtained from Ministry of Health Drug Price List, Price List of
Social Security Institution Health Implementation Guideline
Appendix 2/D and 8, respectively. Clinical and economic out-
comes: The clinical outcome measure is the proportion of
patients responding. The model takes into consideration all of
direct costs associated with the treatment, i.e. antifungal medi-
cations, treatment of side effects and tests. Because the time
horizon of the model is shorter than 1-year, costs are not
discounted. RESULTS: Total costs and response rates are
€2,560/0.40, €8.900/0.47 and €3.790/0.32 for itraconazole,
voriconazole and amphotericin-B, respectively. When compared
with amphotericin-B, additional response rate that is gained
with itraconazole is 0.08. This gain is obtained with €1230 less
cost. Incremental response rate that is gained with voriconazole
is 0.07. This gain is obtained with €6,350 extra cost, i.e. in-
cremental cost-effectiveness ratio (ICER) is €91,000/response.
One-way sensitivity analyses prove that results of the study are
strong. CONCLUSIONS: In the treatment of aspersillosis,
itraconazole is the dominant therapy in comparison to
amphotericine-B. Compared to voriconazole, itraconazole is the
cost-effective therapy option with the ICER of €82,800/
response for voriconazole.
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OBJECTIVES: Since mortality rate due to invasive fungal infec-
tions (IFI) associated with febrile neutropenia (FN) is very high,
empirical antifungal treatment is the mainstay of treatment in
patients with FN. The aim of the study is to compare the cost-
effectiveness of parenteral itraconazole with amphotericin-B
in empirical treatment of IFIs in cancer patients with FN.
METHODS: Model: Decision tree modeling is used in the cal-
culation of cost-effectiveness of options. The time horizon con-
sidered in the model is 20 days. The study has been performed
from the health care payer perspective. Patient group: Cancer
patients older than 18 years, with persistent fever despite anti-
infective treatment. Data sources: The clinical data are acquired
from published clinical studies. Resource use data are based on
expert panel. Prices of medications, institutional discount rates
and other costs related to the treatment obtained from Ministry
of Health Drug Price List, Price List of Social Security Institu-
tion Health Implementation Guideline Appendix 2/D and 8.
Clinical and economic outcomes: Clinical outcome is response
to the treatment. Direct medical costs that are considered are
the costs related with antifungal treatment and side effects.
Because the time horizon of the model is shorter than 1 year,
costs are not discounted. The results are presented as additional
cost per additional response (ICER). Number-needed-to-treat
(NNT) values are also calculated. RESULTS: Response rates
are 0.59 and 0.61, and total costs are €2460 and €2773for
itraconazole and amphotericin-B, respectively. ICER is calcu-
lated as €14.898/response rate for amphotericin-B. NNT values
are 1.69 and 1.64 for itraconazole and amphotericin-B, respec-
tively. A total of €390 will be saved for equal clinical outcome,
if itraconazole is used instead of amphotericin-B. One-way sen-
sitivity analyses prove that the results of the study are strong.
CONCLUSIONS: Itraconazole is a cost-effective treatment
modality in the empirical treatment of IFIs in FN patients in
Turkey.
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OBJECTIVES: Facial lipoatrophy is a signiﬁcant problem related
to antiretroviral therapy for people living with HIV. The only
intervention currently available is the surgical correction with
facial ﬁllers. Objective of this study was to evaluate efﬁcacy and
efﬁciency of injection of various ﬁllers: 1) poly-L-lactid acid; 2)
polyacrylamide hydrogel; and 3) hyaluronic acid + tricalcium
phosphate. METHODS: Cost-effectiveness analysis (CEA) was
performed on the results of a randomized controlled clinical trial
comparing a surgical correction of lipoatrophy versus the usual
clinical care without intervention, over six-month follow-up.
Clinical information was collected with the facial lipoatrophy
scale (possible score 0 = normal, to 3 = severe lipodystrophy).
Direct costs (costs of surgeon, ﬁllers, chirurgical instruments)
were evaluated from the service supplier’s perspective in Italy and
analysed according to prices and tariffs applied in 2008. Data
from 67 patients per arm were collected at baseline and at 0–6
time points. RESULTS: Lipoﬁlling intervention resulted in a
lipoatrophy improvement, with a mean  SD change in facial
lipoatrophy scale of -3.0  0.9. To implement this surgical pro-
cedure, service supplier should sustain an overall cost mean cost
of €2126.42 per patient, corresponding to an incremental cost-
effectiveness ratio of €708.66 per unit of improved facial lipoat-
rophy. CONCLUSIONS: According to preliminary results,
lipoﬁlling intervention for lipoatrophy in HIV patients is cost-
effective: to obtain a decrease of one grade of lipoatrophy, a cost
of €708.66 is expected to be sustained. Information obtained
with this study, can be helpful to make appropriate decisions for
the provision of optimal health care for these patients.
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OBJECTIVES: To perform economical evaluation of etravirine
(ETR) in treatment-experienced HIV-1-infected patients in
Russian health care system. METHODS: The modeled study was
performed. Multicenter randomized studies DUET 1 and 2 were
used as a basis for the model. Cost-effectiveness of ETR com-
pared to placebo, both given with a background regimen (BR) of
nucleoside reverse transcriptase inhibitors, darunavir/ritonavir
and optional enfuvirtide, was assessed. Costs of antiretroviral
therapy for 24 weeks were calculated from the point of Russian
health care system view. Proportion of patients receiving different
drugs and dosing regimen were extracted from DUET 1 and 2
trials. Effect was measured in proportion of patients with viral
load less than 50 copies/ml. Limitation of the model was that
emtricitabine and tenofovir used in BR in both groups have no
market authorization in Russia and were excluded from the
model. Similar proportion of patients in both groups received
these drugs, thus this limitation did not inﬂuence the incremental
cost-effectiveness ratio (ICER). One-way sensitivity analysis was
performed. RESULTS: According to DUET studies ETR was
much more effective than placebo (59 vs 41% patients achieved
viral load <50 copies/ml, p < 0,001), while cost of treatment
(without emtricitabine and tenofovir) was more for ETR than
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